Engineered live biotherapeutic products: design decisions, failure modes, and clinical translation
- 1Key Laboratory of Artificial Organs and Computational Medicine of Zhejiang Province, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren University
- 2State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine
Abstract
Engineered live biotherapeutic products (LBPs) are viable microorganisms deliberately modified to perform a therapeutic function in a patient. Recombinant therapeutic strains are considered separately from conventional probiotics, donor-derived microbiota products, vaccines, living diagnostics, environmental systems, and systemically administered oncolytic bacteria. Selected oncology platforms share engineering constraints with LBPs, although their classification as LBPs depends on the specific therapy. The target product profile sets the niche, route, and exposure requirements against which chassis, genetic control, and payload release are assessed. Fitness costs, genetic stability, basal leakage, and clearance constrain circuit complexity. Formulation and manufacturing must preserve viability and mechanism-linked potency, with process control and independent containment layers evaluated quantitatively during development. Human studies of engineered metabolic strains support feasibility, short-term tolerability, clearance, and pharmacodynamic activity, although broad or durable clinical benefit has not yet been shown. Microbiota products approved by the U.S. Food and Drug Administration (FDA) provide regulatory precedents for live microbial medicines, with approval specific to each unengineered product. Clinical trials require separate assessment of target engagement and patient benefit.
Related
- Editorial: The breast cancer tumor microenvironment: from model systems to clinical translation
- Emerging Technologies in Cardiovascular Disease Modeling: Bridging Basic Science and Clinical Translation
- Avidity-controlled biotherapeutic delivery systems for the treatment of ischemia-reperfusion acute kidney injury
- PET Imaging of Tumor-Associated Macrophage Dynamics and Response to Clinical Treatment for Potential Translation
- TRUEDA overturns replicated, decontaminated low-biomass disease-microbe associations and clinical decisions, recovers true pathogens and outperforms every decontamination method
BibTeX
@article{shen2026engineered,
title = {{Engineered live biotherapeutic products: design decisions, failure modes, and clinical translation}},
author = {Sijia Shen and Junsheng Zhao and Hainv Gao},
journal = {Frontiers in Microbiology},
year = {2026},
month = oct,
doi = {10.3389/fmicb.2026.2002085},
url = {https://www.frontiersin.org/articles/10.3389/fmicb.2026.2002085/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Engineered live biotherapeutic products: design decisions, failure modes, and clinical translation
AU - Sijia Shen
AU - Junsheng Zhao
AU - Hainv Gao
PY - 2026
DA - 2026/10/16
JO - Frontiers in Microbiology
DO - 10.3389/fmicb.2026.2002085
UR - https://www.frontiersin.org/articles/10.3389/fmicb.2026.2002085/full
AB - Engineered live biotherapeutic products (LBPs) are viable microorganisms deliberately modified to perform a therapeutic function in a patient. Recombinant therapeutic strains are considered separately from conventional probiotics, donor-derived microbiota products, vaccines, living diagnostics, environmental systems, and systemically administered oncolytic bacteria. Selected oncology platforms share engineering constraints with LBPs, although their classification as LBPs depends on the specific therapy. The target product profile sets the niche, route, and exposure requirements against which chassis, genetic control, and payload release are assessed. Fitness costs, genetic stability, basal leakage, and clearance constrain circuit complexity. Formulation and manufacturing must preserve viability and mechanism-linked potency, with process control and independent containment layers evaluated quantitatively during development. Human studies of engineered metabolic strains support feasibility, short-term tolerability, clearance, and pharmacodynamic activity, although broad or durable clinical benefit has not yet been shown. Microbiota products approved by the U.S. Food and Drug Administration (FDA) provide regulatory precedents for live microbial medicines, with approval specific to each unengineered product. Clinical trials require separate assessment of target engagement and patient benefit.
SN - 1664-302X
ER -